scholarly journals L’adenocarcinoma prostatico: un nuovo approccio diagnostico integrato finalizzato alla scelta terapeutica

2016 ◽  
Vol 5 (1) ◽  
Author(s):  
A. Delle Fave ◽  
S. Erra
Keyword(s):  
Prostate Cancer ◽  
Needle Biopsy ◽  
Potential Role ◽  
Clinical Decision Making ◽  
Clinical Presentation ◽  
Molecular Targets ◽  
Clinical Decision ◽  
Growth Patterns ◽  
Individual Assessment

Prostate cancer is different in clinical presentation , histopathological tumor growth, patterns and survival than others cancer. Therefore, individual assessment of a tumor’s aggressive potential is crucial for clinical decision-making in men with prostate cancer. Here we discuss the potential role of ERG and CD117 as a prognostic factors and molecular targets in needle biopsy on prostate cancer.

scholarly journals Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
A. Marije Hoogland ◽  
Charlotte F. Kweldam ◽  
Geert J. L. H. van Leenders
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
Molecular Markers ◽  
Radical Prostatectomy ◽  
Clinical Decision Making ◽  
Clinical Presentation ◽  
Prognostic Markers ◽  
Clinical Decision ◽  
Growth Patterns ◽  
Individual Assessment

Prostate cancer is diverse in clinical presentation, histopathological tumor growth patterns, and survival. Therefore, individual assessment of a tumor’s aggressive potential is crucial for clinical decision-making in men with prostate cancer. To date a large number of prognostic markers for prostate cancer have been described, most of them based on radical prostatectomy specimens. However, in order to affect clinical decision-making, validation of respective markers in pretreatment diagnostic needle-biopsies is essential. Here, we discuss established and promising histopathological and molecular parameters in diagnostic needle-biopsies.

scholarly journals COVID-19: Potential role of prophylactic anticoagulation in preventing thrombotic events and mortality. Narrative review

2021 ◽  
Vol 3 (2) ◽  
pp. 122-129
Author(s):  
Maximiliano Gabriel Castro ◽  
◽  
Gisel Cuevas ◽  
Keyword(s):  
Potential Role ◽  
Clinical Evidence ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Narrative Review ◽  
Randomized Controlled ◽  
Prophylactic Dose ◽  
Published Evidence ◽  
Prophylactic Anticoagulation

The COVID-19 pandemic and the limited therapeutic arsenal available strain daily clinical practice. Guidelines have recently recommended routine anticoagulation of hospitalized COVID-19 patients. However, apart from the expert panels’ experience, the provenance of this recommendation is not clear, due to the scarce published evidence. We provide a narrative review with the objective of unraveling the rationale for this practice. First, we analyze the biochemical, histopathological and clinical evidence for a pro-thrombotic profile in COVID-19 patients. Then, we present the clinical data from previous studies and discuss to what extent they aid in clinical decision-making. We conclude that, in the absence of randomized controlled trials, which are of utmost importance, prophylactic-dose anticoagulation should be offered to critically ill patients hospitalized for COVID-19 pneumonia, particularly those with high d-dimer levels, since they are the population most likely to benefit from it.

scholarly journals Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids

2021 ◽  
pp. 1192-1199
Author(s):  
Gianluca Mauri ◽  
Erika Durinikova ◽  
Alessio Amatu ◽  
Federica Tosi ◽  
Andrea Cassingena ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Decision Making ◽  
Drug Screening ◽  
Potential Role ◽  
Clinical Decision Making ◽  
Clinical Decision

The Indaba in African Values-Based Practice

2015 ◽  
Author(s):  
C.W. van Staden ◽  
K. W. M. Fulford
Keyword(s):  
Decision Making ◽  
Potential Role ◽  
Clinical Decision Making ◽  
Family Members ◽  
Clinical Decision ◽  
Her Family ◽  
African Context ◽  
Key Features ◽  
Communicative Processes

This chapter shows how a particular kind of meeting, called in isiZulu the indaba, contributes toBatho Pele, an African values-based practice. First, it explores the challenge of values diversity, including what it means to respect diversity of values, and the different responses to the challenge from regulatory ethics and from values-based practice. It then explores the challenge of diversity in an African context through the story of a real (though biographically disguised) person, Ms. Precious Pelo, her family members and clinicians. Ms. Pelo’s story shows the need for substantive (process-focused) rather than merely executive (outcomes-focused) communicative processes in responding to the challenge of values diversity in clinical decision-making. Finally, it describes part of an indaba convened for Ms. Pelo, its opening minutes illustrating many of the key features ofBatho Pele. We conclude with an indication of the potential role of indabas in other areas of values-based practice.

What is the role of microRNA-301A expression as a diagnostic and predictive marker of biochemical recurrence for prostate cancer?

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 19-19
Author(s):  
Adnan Dervishi ◽  
Samarpit Rai ◽  
Kristy Doan Nguyen ◽  
Thomas Michael FitzGibbon ◽  
Paul Knoll ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Clinical Decision Making ◽  
Specific Antigen ◽  
Predictive Marker ◽  
Clinical Decision ◽  
Definitive Treatment ◽  
Serum Samples ◽  
Prostate Hyperplasia

19 Background: Prostate specific antigen (PSA) screening for prostate cancer (PCa) remains controversial, due to its association with an increase in overdiagnosis of clinically insignificant PCa, and overtreatment. Hence, the need for more specific biomarkers to detect PCa and determine its prognosis. MicroRNA expression has previously been demonstrated as a biomarker to detect several malignancies. Studies suggest that microRNA-301a (miR-301a) inhibits the pro-apoptotic function of RUNX3, a transcription factor, and consequently activates ROCK1-mediated survival signaling in PCa. This study establishes the role of miR-301a as a reliable biomarker that can distinguish between patients with benign prostate hyperplasia (BPH) and PCa, and predict biochemical recurrence (BCR) after definitive treatment of PCa. Methods: Serum samples and tissue from prostate biopsies were collected from patients with an elevated PSA prospectively. The expression of miR- 301a was measured via reverse transcriptase-polymerase chain reaction. Additionally, miR-301a expression was retrospectively evaluated in prostatic tissue of 50 patients with PCa, including benign tissue, and correlated with clinico-pathological characteristics to predict BCR. Immunohistochemistry was performed to confirm the molecular target of miR-301a in cancerous tissue. Results: miR-301a demonstrated a significantly higher expression (p = 0.013) in both PCa tissue (Gleason 6 & 7 PCa) and serum samples (p = 0.011) when compared to BPH. Expression of miR-301a in Gleason 6 & 7 prostatectomy specimens positively correlated with patients who developed BCR when compared to patients who did not. When compared to the current nomogram for the prediction of PCa (i.e., PSA, age, race, Gleason score, and family history), incorporation of miR-301a was associated with a superior prediction of BCR at three years post-prostatectomy. Conclusions: miR-301a expression is a valuable tool for diagnosing PCa in patients with an elevated PSA. Combining miR-301a with PSA is associated with better risk stratification of PCa patients, and may help facilitate clinical decision making.

Sign in / Sign up

Export Citation Format

Share Document